home / stock / bbio / bbio news

BBIO News and Press, BridgeBio Pharma Inc. From 11/08/25

Stock Information
Company Name: BridgeBio Pharma Inc.
Stock Symbol: BBIO
Market: NASDAQ
Website: bridgebio.com
Menu
BBIO BBIO Quote BBIO Short BBIO News BBIO Articles BBIO Message Board
Get BBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
BBIO - Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk r...
BBIO - BridgeBio to Participate in November Investor Conferences

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats ...

BBIO - BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the Amer...

BBIO - BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts

2025-10-31 14:33:26 ET ... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts
BBIO - BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue

2025-10-29 22:57:08 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript BridgeBio Pharma, Inc. 2025 Q3 - Results - Earnings Call Presentation BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in AD...

BBIO - BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

2025-10-29 22:56:25 ET BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

BBIO - BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.06, revenue of $120.7M beats by $14.65M

2025-10-29 16:04:15 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study - Slid...
BBIO - BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 3...

BBIO - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript

2025-10-29 12:06:35 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study October 29, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Discusses Positive Ph...

BBIO - BBIO Price Target Alert: $90.00. Issued by H.C. Wainwright

2025-10-29 10:22:37 ET from H.C. Wainwright issued a price target of $90.00 for BBIO on 2025-10-29 13:28:45. The adjusted price target was set to $90.00. At the time of the announcement, BBIO was trading at $65.7338. The overall price target consensus is at $72.25 with h...
Previous 10 Next 10